Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Previously Treated Metastatic Renal Cell Carcinoma
NCT00061178Phase 3Withdrawn
- Sponsor
- Genentech
- Modality
- Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Bevacizumab Arm with Placebo Arm (2 arms). Status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00061178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061178.